424
Participants
Start Date
September 25, 2013
Primary Completion Date
February 1, 2016
Study Completion Date
January 11, 2019
Enzalutamide
Participants received 4 capsules (40 mg each) of enzalutamide orally once a day, for a total daily dose of 160 mg. Treatment was given with or without food and as close as possible to the same time each day.
Site BE32004, Anderlecht
Site AU61005, Randwick
Site AU61011, Sydney
Site AU61012, Kogarah
Site AU61001, Tweed Heads
Site NZ64001, Hamilton
Site AU61004, Ballarat
Site AR54005, San Miguel de Tucumán
Site AU61002, Nambour
Site AR54003, Córdoba
Site AU61007, Adelaide
Site BE32001, Kortrijk
Site HU36002, Sopron
Site TW88603, Taipei
Site US10001, New York
Site US10014, New York
Site US10026, The Bronx
Site CZ42004, Prague
Site DE49003, Berlin
Site US10039, Syracuse
Site CZ42002, Prague
Site IL97208, Nahariya
Site IT39001, Cremona
Site US10016, Durham
Site ES34006, Madrid
Site ES34001, Pamplona
Site IL97205, Haifa
Site FI35802, Tampere
Site SE46001, Gothenburg
Site IL97202, Kfar Saba
Site IT39005, Meldola
Site DE49001, Münster
Site US10024, Detroit
Site IL97206, Petah Tikva
Site IT39002, Arezzo
Site IL97207, Ramat Gan
Site FR33002, Lyon
Site IL97201, Be’er Ya‘aqov
Site DE49009, Nürtingen
Site US10008, Dallas
Site FR33004, Rouen
Site TW88601, Kaohsiung City
Site IL97203, Beersheba
Site FI35801, Oulu
Site IL97204, Jerusalem
Site FR33005, Suresnes
Site US10025, Seattle
Site US10005, Anchorage
Site SG65002, Singapore
Site CL56003, Viña del Mar
Site CL56002, Temuco
Site CL56001, Temuco
Site CL56004, Santiago
Site AR54001, Berazategui
Site AR54006, Ciudad Autonoma de BuenosAires
Site AR54002, Buenos Aires
Site AR54004, Santa Fe
Site BE32003, Liège
Site CA15005, Abbotsford
Site CA15014, Halifax
Site CA15004, Brampton
Site CA15010, Scarborough Village
Site CA15001, Québec
Site FI35803, Helsinki
Site IT39003, Roma
Site KR82006, Seongnam-si
Site KR82007, Seoul
Site KR82003, Seoul
Site KR82001, Seoul
Site KR82004, Seoul
Site ES34007, L'Hospitalet de Llobregat
Site ES34005, Sabadell
Site ES34003, Barcelona
Site ES34004, Barcelona
Site SE46002, Örebro
Site GB44002, Sutton
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
INDUSTRY
Astellas Pharma Global Development, Inc.
INDUSTRY